[First-line chemotherapy in advanced ovarian cancer].
Colombo
N
N
Divisione di Ginecologia, Istituto Europeo di Oncologia, Milano, Italia.
Parma
G
G
Caspani
G
G
Donesana
P
P
Marinetti
E
E
Mangioni
C
C
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000453:epidemiology; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D017239:Paclitaxel / Q000627:therapeutic use; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel; D002945:Cisplatin